OPRX

+ Watchlist + Portfolio

OptimizeRx Corp.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.39
52-Week Range: $4.54 – $22.25
Market Cap: $161.42M
P/E (TTM): 35.71
EPS (TTM): 0.24
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.23
PEG Ratio: 1.61
Return on Equity: 3.67%
Return on Assets: 4.22%
Gross Margin: 73.22%
Operating Margin: -0.43%
Profit Margin: 4.66%
Current Ratio: 5.58
Debt/Equity: 0.15
Total Debt: $19.48M
Free Cash Flow: $15.76M
Revenue Growth: -29.80%
Earnings Growth: —
Enterprise Value: $156.81M

OPRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$62.45M	$71.52M	$92.13M	$109.43M
Cost of Revenue	$23.48M	$28.62M	$32.75M	$35.83M
Gross Profit	$38.97M	$42.90M	$59.38M	$73.59M
Selling, General & Admin	$49.24M	$58.02M	$61.27M	$57.21M
Operating Expenses	$51.26M	$60.42M	$65.59M	$61.53M
Operating Income	-$12.29M	-$17.52M	-$6.22M	$12.06M
EBITDA	-$9.42M	-$21.31M	-$8.90M	$16.57M
Pretax Income	-$11.44M	-$25.16M	-$19.39M	$6.95M
Income Tax	$0.00	-$7.60M	$725.00K	$1.82M
Net Income	-$11.44M	-$17.57M	-$20.11M	$5.13M
Diluted EPS	-0.64	-1.03	-1.10	0.27
Diluted Shares	17.78M	17.12M	18.29M	19.00M

OPRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.21M	$13.85M	$13.38M	$23.36M
Receivables	$22.16M	$37.29M	$38.21M	$38.50M
Current Assets	$98.58M	$54.33M	$53.97M	$64.72M
Total Assets	$134.65M	$183.37M	$171.17M	$176.92M
Current Liabilities	$8.40M	$17.88M	$18.65M	$21.26M
Long-Term Debt	—	$34.23M	$30.82M	$21.42M
Total Debt	$234.43K	$36.82M	$33.19M	$26.10M
Total Liabilities	$8.54M	$56.82M	$54.17M	$48.62M
Retained Earnings	-$46.69M	-$64.26M	-$84.37M	-$79.24M
Shareholders' Equity	$126.11M	$126.55M	$117.00M	$128.29M
Working Capital	$90.18M	$36.45M	$35.32M	$43.45M
Net Debt	—	$22.38M	$19.44M	$2.31M

OPRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$10.65M	-$7.24M	$4.89M	$18.71M
Capital Expenditure	-$244.56K	-$871.00K	-$450.00K	—
Free Cash Flow	$10.41M	-$8.11M	$4.44M	$18.71M
Depreciation & Amortisation	$2.02M	$2.40M	$4.33M	$4.33M
Stock-Based Compensation	$15.75M	$13.72M	$11.47M	$6.96M
Investing Cash Flow	-$58.18M	-$25.34M	-$450.00K	$68.00K
Financing Cash Flow	-$18.95M	$28.22M	-$4.91M	-$8.80M
Share Repurchases	-$20.02M	-$7.52M	$0.00	—
Net Change in Cash	-$66.47M	-$4.36M	-$472.00K	$9.98M

OPRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$21.93M	$29.20M	$26.07M	$32.24M	$19.84M	$20.50M
Cost of Revenue	$8.58M	$10.56M	$8.55M	$8.14M	$4.91M	$4.82M
Gross Profit	$13.34M	$18.64M	$17.52M	$24.10M	$14.93M	$15.69M
Research & Development	$3.25M	$3.09M	—	—	$3.40M	$3.27M
Selling, General & Admin	$11.10M	$11.26M	$14.39M	$14.09M	$10.07M	$11.44M
Operating Expenses	$15.45M	$15.43M	$15.47M	$15.16M	$14.54M	$15.78M
Operating Income	-$2.10M	$3.21M	$2.05M	$8.94M	$396.00K	-$88.00K
EBITDA	-$881.00K	$4.41M	$3.28M	$9.79M	$1.57M	$1.09M
Pretax Income	-$3.27M	$1.73M	$1.05M	$7.47M	-$644.00K	-$1.10M
Income Tax	-$1.07M	$199.00K	$270.00K	$2.45M	-$149.00K	-$393.00K
Net Income	-$2.20M	$1.53M	$779.00K	$5.02M	-$495.00K	-$703.00K
Diluted EPS	-0.12	0.08	0.04	0.26	-0.03	-0.04
Diluted Shares	18.47M	19.02M	19.46M	19.38M	18.76M	18.79M

OPRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$16.57M	$16.59M	$19.52M	$23.36M	$20.17M	$24.10M
Receivables	$32.83M	$34.16M	$33.97M	$38.50M	$32.86M	$27.12M
Current Assets	$51.71M	$54.08M	$56.32M	$64.72M	$56.16M	$54.15M
Total Assets	$167.77M	$169.26M	$170.32M	$176.92M	$167.26M	$164.32M
Current Liabilities	$18.35M	$21.06M	$18.47M	$21.26M	$10.46M	$9.71M
Long-Term Debt	$29.19M	$25.13M	$24.80M	$21.42M	$21.34M	$17.76M
Total Debt	$32.80M	$28.98M	$28.61M	$26.10M	$23.72M	$19.48M
Total Liabilities	$51.50M	$49.98M	$48.06M	$48.62M	$37.65M	$33.23M
Retained Earnings	-$86.57M	-$85.03M	-$84.26M	-$79.24M	-$79.73M	-$80.43M
Shareholders' Equity	$116.27M	$119.28M	$122.26M	$128.29M	$129.61M	$131.08M
Working Capital	$33.36M	$33.02M	$37.85M	$43.45M	$45.71M	$44.44M
Net Debt	$15.92M	$11.84M	$8.58M	$2.31M	$3.17M	—

OPRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$3.86M	$4.56M	$3.20M	$7.09M	-$467.00K	$8.61M
Capital Expenditure	-$84.00K	-$44.00K	-$10.00K	—	-$21.00K	-$35.00K
Free Cash Flow	$3.78M	$4.52M	$3.19M	$7.23M	-$488.00K	$8.58M
Depreciation & Amortisation	$1.09M	$1.07M	$1.08M	$1.08M	$1.06M	$1.06M
Stock-Based Compensation	$1.56M	$1.49M	$1.96M	$1.96M	$1.83M	$2.21M
Investing Cash Flow	-$84.00K	-$44.00K	-$10.00K	$206.00K	-$21.00K	-$35.00K
Financing Cash Flow	-$587.00K	-$4.50M	-$258.00K	-$3.45M	-$2.71M	-$4.66M
Net Change in Cash	$3.19M	$12.00K	$2.93M	$3.85M	-$3.20M	$3.92M

Market Snapshot

About

OptimizeRx operates a digital health messaging platform connecting pharmaceutical companies with healthcare providers at the point of care, facilitating patient access programs and electronic prescribing.